Taiwan Kao Su-Chin Chang, founder and chairman of Weidar Chemical and Pharmaceutical, describes the robust development and international expansion of this historical domestic pharmaceutical manufacturer and the company’s enduring commitment to maintaining the excellence of its manufacturing capacity, which has allowed Weidar to establish itself as one of the foremost generics…
Taiwan Lawrence Gan, President and CEO of Taiwan’s Development Center for Biotechnology (DCB) explains his vision and strategy to enhance DCB’s R&D expertise by adopting some of the best practices of the corporate world. You became head of Taiwan’s Development Center for Biotechnology after having held prestigious positions in the US…
Taiwan Thomas Yuan, the CEO of TFBS Bioscience, documents the tailored added-value that this fast-growing product testing company strives to bring to emerging pharmaceutical and biotech companies in the Asia Pacific region, while TFBS already stands out as the only service provider of its kind in Taiwan and one of the…
Taiwan Grace Yeh, Founder, President, and CEO of PharmaEngine, one of the most eye-catching success stories to recently emerge from Taiwan’s maturing biopharmaceutical sector, documents the main success factors that have allowed PharmaEngine to become the first Taiwan-based company to receive FDA approval for a locally-developed oncology treatment, as well as…
Taiwan Du-Shieng Chien, President & CEO of TaiRx, a Taiwan-based biopharmaceutical company focused on unmet medical needs, provides insights into the recent development of CVM 1118, a revolutionary cancer treatment targeting breakthrough mechanisms to tackle tumor development and the first drug of its kind to have already started clinical trials in…
Taiwan This graph shows the revenues from the biotech sector in Taiwan between 2004 and 2012, broken down to show applied biotech, pharmaceuticals and medical devices.
Taiwan This graph looks at the market growth in the Taiwanese pharmaceutical sector since 2007, and predicts the growth rate until 2017, estimating a CAGR of 4.62 percent.
Taiwan This graph shows the total revenues and market value of the Taiwanese biotech sector between 2007 and 2013, as well as the number of listed companies in that sector over the same period.
china Signed in June 2010, the Economic Cooperation Framework Agreement (ECFA) between Taiwan and China was set to reduce tariffs and commercial barriers between the two countries. Obviously, such a deal means a lot to Taiwanese companies; arguably much more than it does to Chinese businesses. But just because the agreement…
Biosimilars Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent a bubble burst, and the crucial next steps in maintaining the momentum to continue growth within the industry. Please start…
liposome A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to “break out from the typical dilemma of ordinary biotech firms—to either engage in low cost, high competition generic drug manufacturing or expensive, time-consuming new drug development—by opening up a third road of…
health insurance Taiwan’s current health minister reflects on Taiwan’s prestigious healthcare system, the problems in the first generation health insurance system that were fixed in the second, and strategies to rectify the continuous problem of price cuts. Shortly following our interview, the heretofore-Department of Health will become the Ministry of Health and…
See our Cookie Privacy Policy Here
